Research highlights the clinical value of amyloid-ß PET scans, which detect the presence of amyloid-beta plaques in the brain - one of the hallmarks of Alzheimer’s disease. Studies also revealed an underutilization of amyloid-ß PET imaging in clinical care, contributing to misdiagnosis of dementia. Read more.
Sleep health may be target for early intervention
Self-reported poor sleep was associated with a greater presence of several cerebrospinal fluid (CSF) biomarkers of Alzheimer’s disease, according to a cross-sectional study.
Disrupted sleep or lack of sleep has previously been linked to a greater risk for brain amyloid plaque on PET imaging, but the study is among the first to show an association between poor sleep and amyloid and other biological markers for Alzheimer’s disease in the spinal fluid, wrote Barbara Bendlin, PhD, of the University of Wisconsin-Madison, and colleagues. Read more.
In the last decades, in addition to conventional imaging techniques and magnetic resonance imaging (MRI), 18F-fluorodeoxyglucose positron emission tomography/computed tomography (FDG PET/CT) has been shown to be relevant in the detection and management of breast cancer recurrence in doubtful cases in selected groups of patients. While there are no conclusive data indicating that imaging tests, including FDG PET/CT, produce a survival benefit in asymptomatic patients, FDG PET/CT can be useful for identifying the site of relapse when traditional imaging methods are equivocal or conflicting and for identifying or confirming isolated loco-regional relapse or isolated metastatic lesions. Read more.
Dr. Robert S. Miletich, interim chair and professor at the Jacobs School of Medicine at the University at Buffalo, believes that nuclear medicine will one day be as important to neuroscience as it is to cardiology. Read more.
New technique could improve tumour diagnosis and treatment
A new automated fluorine-18 labelling procedure could make this useful radioisotope easier to use in medical imaging.
Positron emission tomography (PET) is a nuclear medicine technique that provides a non-invasive way to diagnose and design treatment for tumours. The technique monitors how positron-emitting radionuclides bound to biological targeting molecules accumulate in the body. The radionuclide accumulates in cancerous tissue, and its concentration provides both qualitative and quantitative information about the tumour. Read more.